CRUSE®—An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria

IF 4.6 2区医学 Q2 ALLERGY Clinical and Translational Allergy Pub Date : 2024-01-03 DOI:10.1002/clt2.12328

Sophia Neisinger, Bernardo Sousa Pinto, Aiste Ramanauskaite, Jean Bousquet, Karsten Weller, Martin Metz, Markus Magerl, Emek Kocatürk, Ivan Cherrez-Ojeda, Ana M. Gimenez-Arnau, Claudio Alberto S. Parisi, Sabine Altrichter, Luis Felipe Ensina, Laurence Bouillet, Riccardo Asero, Margarida Gonçalo, Carole Guillet, Krzysztof Rutkowski, Jonathan A. Bernstein, Hannah Hardin, Kiran Godse, Zenon Brzoza, Jose Ignacio Larco Sousa, Simon Francis Thomsen, Martijn van Doorn, Michihiro Hide, Young-Min Ye, Staffan Vanderse, Lāsma Lapiņa, Jonny Peter, Zuotao Zhao, Lianyi Han, Iman Nasr, Heike Rockmann-Helmbach, Jennifer Astrup Sørensen, Rabia Öztaş Kara, Natalja Kurjāne, Andrii I. Kurchenko, Igor Kaidashev, Vladyslav Tsaryk, Roman Stepanenko, Marcus Maurer

{"title":"CRUSE®—An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria","authors":"Sophia Neisinger, Bernardo Sousa Pinto, Aiste Ramanauskaite, Jean Bousquet, Karsten Weller, Martin Metz, Markus Magerl, Emek Kocatürk, Ivan Cherrez-Ojeda, Ana M. Gimenez-Arnau, Claudio Alberto S. Parisi, Sabine Altrichter, Luis Felipe Ensina, Laurence Bouillet, Riccardo Asero, Margarida Gonçalo, Carole Guillet, Krzysztof Rutkowski, Jonathan A. Bernstein, Hannah Hardin, Kiran Godse, Zenon Brzoza, Jose Ignacio Larco Sousa, Simon Francis Thomsen, Martijn van Doorn, Michihiro Hide, Young-Min Ye, Staffan Vanderse, Lāsma Lapiņa, Jonny Peter, Zuotao Zhao, Lianyi Han, Iman Nasr, Heike Rockmann-Helmbach, Jennifer Astrup Sørensen, Rabia Öztaş Kara, Natalja Kurjāne, Andrii I. Kurchenko, Igor Kaidashev, Vladyslav Tsaryk, Roman Stepanenko, Marcus Maurer","doi":"10.1002/clt2.12328","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Chronic spontaneous urticaria (CSU) is unpredictable and can severely impair patients' quality of life. Patients with CSU need a convenient, user-friendly platform to complete patient-reported outcome measures (PROMs) on their mobile devices. CRUSE<sup>®</sup>, the Chronic Urticaria Self Evaluation app, aims to address this unmet need.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>CRUSE<sup>®</sup> was developed by an international steering committee of urticaria specialists. Priorities for the app based on recent findings in CSU were defined to allow patients to track and record their symptoms and medication use over time and send photographs. The CRUSE<sup>®</sup> app collects patient data such as age, sex, disease onset, triggers, medication, and CSU characteristics that can be sent securely to physicians, providing real-time insights. Additionally, CRUSE<sup>®</sup> contains PROMs to assess disease activity and control, which are individualised to patient profiles and clinical manifestations.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>CRUSE<sup>®</sup> was launched in Germany in March 2022 and is now available for free in 17 countries. It is adapted to the local language and displays a country-specific list of available urticaria medications. English and Ukrainian versions are available worldwide. From July 2022 to June 2023, 25,710 observations were documented by 2540 users; 72.7% were females, with a mean age of 39.6 years. At baseline, 93.7% and 51.3% of users had wheals and angioedema, respectively. Second-generation antihistamines were used in 74.0% of days.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>The initial data from CRUSE<sup>®</sup> show the wide use and utility of effectively tracking patients' disease activity and control, paving the way for personalised CSU management.</p>\n </section>\n </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.12328","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Allergy","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/clt2.12328","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Chronic spontaneous urticaria (CSU) is unpredictable and can severely impair patients' quality of life. Patients with CSU need a convenient, user-friendly platform to complete patient-reported outcome measures (PROMs) on their mobile devices. CRUSE^®, the Chronic Urticaria Self Evaluation app, aims to address this unmet need.

Methods

CRUSE^® was developed by an international steering committee of urticaria specialists. Priorities for the app based on recent findings in CSU were defined to allow patients to track and record their symptoms and medication use over time and send photographs. The CRUSE^® app collects patient data such as age, sex, disease onset, triggers, medication, and CSU characteristics that can be sent securely to physicians, providing real-time insights. Additionally, CRUSE^® contains PROMs to assess disease activity and control, which are individualised to patient profiles and clinical manifestations.

Results

CRUSE^® was launched in Germany in March 2022 and is now available for free in 17 countries. It is adapted to the local language and displays a country-specific list of available urticaria medications. English and Ukrainian versions are available worldwide. From July 2022 to June 2023, 25,710 observations were documented by 2540 users; 72.7% were females, with a mean age of 39.6 years. At baseline, 93.7% and 51.3% of users had wheals and angioedema, respectively. Second-generation antihistamines were used in 74.0% of days.

Conclusions

The initial data from CRUSE^® show the wide use and utility of effectively tracking patients' disease activity and control, paving the way for personalised CSU management.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

CRUSE®-用于慢性自发性荨麻疹患者监测和管理的创新型移动应用程序

背景慢性自发性荨麻疹（CSU）难以预测，会严重影响患者的生活质量。慢性自发性荨麻疹患者需要一个方便、用户友好的平台，在移动设备上完成患者报告的结果测量（PROMs）。慢性荨麻疹自我评估应用程序 CRUSE® 旨在满足这一尚未满足的需求。方法 CRUSE® 由荨麻疹专家组成的国际指导委员会开发。根据最近对慢性荨麻疹的研究结果，确定了该应用程序的优先事项，即允许患者跟踪和记录自己的症状和用药情况，并发送照片。CRUSE® 应用程序收集患者数据，如年龄、性别、发病时间、诱发因素、用药情况和 CSU 特征，这些数据可安全地发送给医生，提供实时见解。此外，CRUSE® 还包含用于评估疾病活动和控制情况的 PROMs，可根据患者情况和临床表现进行个性化设置。结果 CRUSE® 于 2022 年 3 月在德国推出，目前在 17 个国家免费提供。它根据当地语言进行了调整，并显示针对特定国家的可用荨麻疹药物列表。英语版和乌克兰语版已在全球推出。从 2022 年 7 月到 2023 年 6 月，共有 2540 名用户记录了 25710 次观察结果；其中 72.7% 为女性，平均年龄为 39.6 岁。基线时，分别有 93.7% 和 51.3% 的使用者出现喘息和血管性水肿。74.0%的患者使用了第二代抗组胺药。结论 CRUSE® 的初步数据表明，有效跟踪患者的疾病活动和控制情况具有广泛的用途和效用，为个性化 CSU 管理铺平了道路。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Clinical and Translational Allergy Immunology and Microbiology-Immunology

CiteScore

7.50

自引率

4.50%

发文量

117

审稿时长

12 weeks

期刊介绍： Clinical and Translational Allergy, one of several journals in the portfolio of the European Academy of Allergy and Clinical Immunology, provides a platform for the dissemination of allergy research and reviews, as well as EAACI position papers, task force reports and guidelines, amongst an international scientific audience. Clinical and Translational Allergy accepts clinical and translational research in the following areas and other related topics: asthma, rhinitis, rhinosinusitis, drug hypersensitivity, allergic conjunctivitis, allergic skin diseases, atopic eczema, urticaria, angioedema, venom hypersensitivity, anaphylaxis, food allergy, immunotherapy, immune modulators and biologics, animal models of allergic disease, immune mechanisms, or any other topic related to allergic disease.